• SPYR eyes greater shareholder value, as the move is expected to increase revenues and profitability through fees charged to players for maintenance and trading of planets they “own”
• The blockchain technology integration will also allow SPYR to market planets held in the blockchain to others with space-themed games
• Pocket Starships players will have greater ownership of the planets they buy, and they will be able to execute P2P (player-to-player) transactions with cryptocurrencies, such as bitcoin

SPYR, Inc. (OTC: SPYR) has announced that it is executing the integration of blockchain technology into its Pocket Starships flagship game within its wholly-owned subsidiary, SPYR APPS, LLC (http://ibn.fm/OHREn). The result will be additional revenue from the integration of blockchain into Pocket Starships, the company said. In addition, the technology, marketed through SPYR, will also be available to others who have developed and published their own space-themed games.

Blockchain will hold planets in the Pocket Starships game. SPYR then anticipates generating more revenue by charging players for maintenance of the planets and by getting a percentage of the revenues on the buying, selling and trading of planets. Each planet held by blockchain will be unique and tradable on the public planet real estate market, SPYR said. Cryptocurrencies, such as bitcoin, can be used to buy and sell planets.

SPYR, Inc., is a Denver-based holding company which is eyeing additional acquisitions within the mobile application, game development and similar verticals markets. Its goal is to expand its holdings, generate more revenue and boost shareholder value by increasing profits.

In a news release, James R. Thompson, CEO and president of SPYR, said, “I believe we have come up with a very exciting way to implement Blockchain technology both within and beyond Pocket Starships. The ability to own a planet that creates in-game resources is something that will appeal to our players and keeping the planet on the blockchain will allow SPYR to work with other developers and publishers to have the planets exist in any number of space-themed games.”

For more information, visit the company’s website at www.SPYR.com

• Company notes record revenues in latest quarterly report
• Global big data revenues expected to approach $80 billion within three to five years
• Blockchain’s security may enhance AI’s data learning to provide greater efficiency options

The world marked 2017 as the year blockchain technology and its derivative applications created real revenue-generating excitement for business, even while differing experts debated whether the transaction-securing tech is truly foundational or simply the market darling of the moment. Among the companies evaluating the changing data landscape was AnalytixInsight, Inc. (TSX.V: ALY) (OTCQB: ATIXF), a dealer in the much older and still nascent technology sector of artificial intelligence. AnalytixInsight has created a proprietary “machine learning” technology to analyze big data and turn it into actionable strategies for the fintech and internal corporate analytics markets, and it is evaluating opportunities to enhance its efficiency via the convergence of data evaluation and data security technologies.

AnalytixInsight, through its flagship product CapitalCube, serves investors and the companies who inform them by providing in-depth analysis on over 50,000 global equities and North American ETFs, company accounting and earnings reports and information about likely future stock and acquisition activity by select corporations — all thanks to its AI capacity. The technology frequently reevaluates itself to maintain a desired investment risk profile while providing regular compliance reporting.

CapitalCube has the ability to provide information in multiple languages, is customizable and can generate reports, earnings analyses, graphs, trend charts and numeric table displays in PDF file format utilizing 100 billion computations each day. Through partnership agreements with Thomson Reuters, The Wall Street Journal, Yahoo Finance and other financial entities, the platform publishes thousands of daily news articles as well.

Another fintech subsidiary, called MarketWall, develops mobile and wearable software for a wide variety of smart devices. Its latest app, attuned to real-time stock trading information and online banking, is expected to launch in 2018 for the 12.6 million customers of Intesa Sanpaolo, Italy’s largest retail bank, with branches located across six European countries. The mobile stock trading application will interface with the bank’s MarketHub trading platform. The app ties as-it-happens market data to company profile information provided by CapitalCube.

A third subsidiary, Euclides Technologies, delivers workforce management data solutions for global-reach corporations through its Field Service Management software. The artificial intelligence platform will empower companies to increase the efficiency of their large-scale operations by tracking employee performance data and establishing customized recommendations for controlling quality. The advent of cloud services also provides companies with options for data processing and implementation that don’t require investments in large-scale infrastructure and security measures.

AnalytixInsight’s AI technology algorithms have the potential to be adapted to almost any data-driven corporate or governmental need, or even entertainment interests such as sports tracking and forecasting.

Analysis portal Statista.com estimated that the global big data industries’ revenues amounted to just under $34 billion in 2017 (http://ibn.fm/DRs5K) with the capacity to grow to nearly $80 billion in the next five years. SNS Research estimated global big data revenues at over $57 billion in 2017 (http://ibn.fm/SVsr9), with a CAGR of about 10 percent growth during the next three years, amounting to about $76 billion by the end of 2020. AnalytixInsight’s most recent quarterly report showed a record revenue level of $1.7 million, a 77 percent increase over the previous quarter and a 600 percent increase over the same period of the previous year.

For more information, visit the company’s website at www.AnalytixInsight.com

Let us hear your thoughts: AnalytixInsight Inc. Message Board

• Company utilizing novel Caribbean blue scorpion venom therapy for immune system boost
• PreveCeutical seeks new ways to treat cancers, metabolic disorders, pain, infectious diseases and cardiovascular disease
• Partnership with University of Queensland researchers advances scientific scope of projects

In the modern health care industry, disease prevention has taken a commanding role as screenings and regularly scheduled physician visits aim to minimize costs that could otherwise spiral out of control once a chronic condition is established. However, the Centers for Disease Control and Prevention report an ongoing concern that Americans are using preventive services at about half the recommended rate (http://ibn.fm/5IfsA). British Columbia-based PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) was founded on the principle that prevention is the best policy in health care and that nature and science may combine to provide an array of innovative, untapped solutions to otherwise unmet clinical needs.

PreveCeutical is taking a new look at ways to combat chronic health concerns such as diabetes and obesity, pain management, neurological disorders and cancer. PreveCeutical developed its CELLB9® oral dilute solution utilizing select peptides from the blue scorpion, which is found only in the Caribbean region. PreveCeutical’s “Nature Identical” research team is building on proprietary chemistry to produce controlled venom peptides that it hopes will be able to halt the progression of cancers, while also exploring the peptides’ potential in responding to other medical concerns related to metabolic disorders, pain, cardiovascular disease and infectious maladies.

During 2017, the company entered a partnership with UniQuest Pty Limited that directs UniQuest to conduct research programs at the University of Queensland in Australia on PreveCeutical’s behalf. The partnership identified development programs for four therapies.

One of those is aimed at assessing pain and inflammation models with the idea of developing non-addictive analgesics for moderate to severe pain. The three-phase research project was expected to last up to 24 months under the terms of the research and option agreement (http://ibn.fm/MXC9z) with the goal of identifying the scorpion peptides and a means of replicating them in a laboratory, rather than having to rely on milking the scorpions for their venom, then screening the peptides in various disease models of interest.

PreveCeutical is also developing a proprietary gel application, called Sol-gels, for delivering a CBD-based medical cannabis formulation directly to the brain. Sol-gels are taken via nasal (systemic) administration and rapidly gel upon contact with mucosal tissue, which paves the way for direct nose-to-brain delivery. This effectively bypasses the stomach and intestines – eliminating first-pass metabolism – and may dramatically improve bioavailability, even compared to nasal sprays and other newer delivery systems. Additionally, the gel stays in the nasal passages, slowly releasing the CBD while keeping it active for up to seven days. The ease of application and its long-lasting effects may be attractive for patients when compared to other delivery systems.

The company’s four-year program targeting diabetes and obesity seeks also to engineer a therapy that recognizes a gene common and overactive in the two ailments. The therapy would “silence” the gene — turning it off to prevent the overproduction of a protein molecule believed to play a role in the declines commonly associated with diabetes and obesity.

Successes in these endeavors would solidify PreveCeutical’s efforts to become recognized as a pioneer in preventative medicine and increased quality of life factors.

For more information, visit the company’s website at www.PreveCeutical.com

Let us hear your thoughts: PreveCeutical Medical Inc. Message Board

• Company has developed and licensed novel drug delivery systems and products for over 15 years
• With 14 patents, Skinvisible has proven efficacy and global reach
• Proposed merger may transform non-opioid pain market

At the cutting edge of innovative drug delivery technology since 1999, Skinvisible, Inc. (OTCQB: SKVI), in a recently announced Letter of Intent of a proposed merger with Quoin Pharmaceuticals, is now expanding its horizons into the global pain management therapeutics market. The pain management therapeutics market is projected to expand at a 3.7 percent CAGR and exceed $83 billion in the United States by 2024 (http://ibn.fm/1wGbq). Skinvisible, through wholly owned subsidiary Skinvisible Pharmaceuticals, Inc., has already developed, licensed and sold multiple dermatology and health care products, as well as various medical treatments, using its patented Invisicare® technology. The proposed merger with Quoin Pharmaceuticals (http://ibn.fm/dJWLM) would combine Skinvisible’s patented and proven novel drug delivery technologies that enhance the delivery of various active ingredients with Quion’s strong pharmaceutical background in post-surgical pain and promising approach to PTSD treatment.

Skinvisible has a long, successful history developing and licensing Invisicare®, its patented polymer technology. Enhancing how drugs are delivered on, in, or through the skin, Invisicare® has proven efficacy in a wide range of dermatology and health care products, including products to treat acne, skin cancers, eczema, fungal infections, inflammation, warts and dermatitis. Broad applications extend to sunscreens, anti-aging products, alcohol-free hand sanitizing lotions, pre-surgical preparations and, now, with a Quoin merger, the enhanced delivery of important non-opioid pain management medications.

With a focus on a lucrative licensing model and over 40 products developed in topical dermatology, Skinvisible has already achieved impressive market traction. The company offers a premium line of scientifically formulated, highly effective skincare products powered by its Invisicare® technology and has revolutionized the topical sunscreen market with Skinbrella®, a patented broad-spectrum 80-minute water-resistant sunscreen that meets or exceeds all FDA requirements.

Last year, Skinvisible completed its first international sale of alcohol-free DermSafe® hand sanitizers in China. DermSafe® utilizes a unique formulation that provides a long-lasting protective barrier that binds to the skin for hours and reduces the spread of germs between people and hard surfaces. In September 2017, the company signed a breakthrough exclusive license agreement with Canopy Growth (TSX: WEED) for two distinct cannabis- and hemp-based topical product lines aimed at enhancing penetration of topically used cannabis products.

With 14 patents granted surrounding its novel drug delivery systems and products, it’s little wonder that Quoin Pharmaceuticals looks to merge with Skinvisible. Delivering enhanced and effective non-opioid pain relief is the current Holy Grail of pharmacology, and Skinvisible’s contribution to what may become transformative pain management delivery shouldn’t be underestimated.

For more information, visit the company’s website at www.Skinvisible.com

Let us hear your thoughts: Skinvisible, Inc. Message Board

• Portfolio of hemp-derived CBD products
• Opening of new production facilities
• New subsidiaries, acquisitions and joint ventures

Earth Science Tech, Inc. (OTC: ETST) is celebrating another year of accomplishment. In 2017, the company churned out a series of advancements that included the launch of new subsidiaries and products and an acquisition, along with entry into marketing, manufacturing and distribution agreements. It also commenced pre-launch human trials of a new product designed to join the fight against opioid addiction. As a result, 2017 revenues were almost twice as much as in 2016. Now, even though the stock is trading at around $1.00, a price target of over $4.00 has been set.

Earth Science is making waves in the hemp-derived cannabinoid (CBD), nutraceutical, pharmaceutical and medical device markets. The company’s activities range from R&D to production to marketing and distribution. It continues to build the networks and infrastructure to launch new products, embarking on a number of joint ventures and acquisitions, and launching new subsidiaries. It has created a new division, Cannabis Therapeutic Inc., to develop proprietary cannabinoid-based nutraceuticals and pharmaceutical products based on its existing CBD patent.

The company also acquired Canna Inno Laboratories Inc., which will allow it access to Canadian government grants. Grant applications have already been filed, and the company anticipates that its first request will be approved in Q1 2018. Earth Science expects that, through this new subsidiary, about half of all R&D expenditures will be covered by grants. A joint venture with Karmavore SuperFood is set to manufacture a new chocolate product, and one with Varsity Group, LLC, a kanna ingredient based e-liquid company, will give Earth Science a presence in the recreational vape/smoke market. Kanna, widely consumed in South Africa, is thought to decrease anxiety.

With these platforms in place, the ETST pipeline is filled with goodies like the CBD Organic Chocolate line and the Strawberry Orange Blossom CBD oil, as well as a pet CBD oil. Earth Science also plans to create two new cannabinoid-based pharmaceutical drugs and three new advanced cannabinoid-based nutraceutical products in collaboration with Smart Medicine, Inc. an independent laboratory based at Le Centre Québecois d’Innovation en Biotechnologie (“CQIB”) in Laval, Québec. In addition, Earth Science is developing proprietary prophylactic therapies to prevent breast cancer, and a treatment to help women with aggressive breast cancer. Additionally, seizing on an opportunity to enter the recreational vape/smoke market, the company launched a new wholly-owned subsidiary, KannaBidioid Inc., in its joint venture with Varsity Group, LLC, to manufacture and distribute vapes/e-liquids and gummy edibles.

In 2017, new manufacturing and shipping facilities were opened. Earth Science commenced leasing a manufacturing facility for the production of the MSN-2 medical device and began the first round of negotiations with foreign health authorities for commercialization of the product. MSN-2, designed to protect women and their future babies from chlamydia, will be launched in 2018 in select countries. In addition, ETST signed an agreement with the Centre de Développement Bioalimentaire du Québec (“CDBQ”), a major force in the agro-food industry in Canada. Based in La Pocatière, Quebec, CDBQ specializes in helping companies develop the processes needed to take a prototype agro-food or nutraceutical product to industrial-scale production for the marketplace. CDBQ boasts a bio-food incubator, which encompasses a 30,000 square foot, $10 million facility that houses seven separate factories equipped with cutting-edge equipment and technology.

Earth Science is also working with the Clinique SIDA Amité (AIDS Friendship Clinic) to conduct an amini-clinical trial, the last trial needed before the MSN-2 device enters molecular diagnostic trials. The company has started pre-launch human trials on a new CBD formula to fight against the U.S. opioid epidemic. The new formula, expected to decrease cravings and the negative effects of withdrawal in addicts, is based on industrial hemp CBD oil mixed with a known natural ingredient proven to help increase dopamine levels.

The hemp-derived CBD market is projected to grow at a CAGR of about 53 percent until 2020, positioning it as the fastest-growing sub-segment within the multi-billion dollar legal cannabis and hemp market. With an eye on that expanding market, ETST plans to launch a Regulation A+ Tier 2 round of financing in 2018. The goal will be to raise $4 million to complete all planned projects.

For more information, visit the company’s website at www.EarthScienceTech.com

• State-sanctioned cannabis businesses forced into cash-only operations due to federal conundrum
• Medical Cannabis Payment Solutions has alternative for cannabis banking that solves cash handling issues
• Company’s proprietary system breaks logjam and provides businesses with competitive advantages

As the scientific evidence of the medical efficacy of marijuana has mounted, multiple states have begun to legalize its use. Ignoring antiquated federal strictures, 29 states now permit medicinal use, with eight states allowing recreational use, and more states are expected to expand legalization this coming year. The acceptance of marijuana throughout the nation has spawned a multi-billion dollar industry, yet it has also created a continuing conundrum for businesses engaged in marijuana transactions. These businesses are legal, yet are unable to open or maintain a bank account. Since the federal government still regards marijuana as an illegal drug, it has created an all-cash nightmare for the cannabis industry. Banks are regulated by the federal government and most won’t touch cannabis cash. A multi-billion dollar cash business invites headaches and trouble. Tax collection, payroll problems, bill payment, assaults and armed robbery all plague an industry that’s expected to exceed $37 billion in the U.S. by 2024. No other industry of this size suffers through such operational and logistical nightmares.

To solve these complex issues, Medical Cannabis Payment Solutions (OTC: REFG) has created the first purpose-built solution to cannabis banking that solves cash handling issues, offers electronic payment and e-commerce features and gives marijuana businesses immediate access to funds while keeping them in compliance with all federal (FinCEN) laws to combat domestic and international money laundering, terrorist financing and other financial crimes. Not only compliant, REFG’s end-to-end payment processing solution finally provides cannabis customers and retailers with high-function payment options other than cash.

REFG’s proprietary Green closed-loop merchant processing system is the first operation of its kind geared to the legal cannabis industry. Not a prepaid or gift card, it is one of the first and only comprehensive card processing operations to break the operational and logistical logjam caused by cash-only transactions in state-sanctioned marijuana businesses. The debit card from Medical Cannabis Payment Solutions can only be used for payment within a state where marijuana is legal and only for cannabis-related products from state-sanctioned vendors. Businesses using the company’s card realize an immediate advantage in reducing risks, meeting regulatory requirements and promoting customer interactions.

By breaking the logjam and providing state-sanctioned marijuana businesses with the first purpose built solution to cannabis banking, including sales tracking and tax collection, Medical Cannabis Payment Solutions is poised to become an indispensable asset to the burgeoning national marijuana industry.

For more information, visit the company’s website at www.MedicalCannabisPaymentSolutions.com

Let us hear your thoughts: Medical Cannabis Payment Solutions Message Board

• CIIX records sharply higher investor relations revenue in 1Q2018 and FY2017 as it expands program offerings for branding clients
• In FY2018, company will focus on new cryptocurrency division as it increases commitment to bitcoin education and hosts bitcoin ATM in lobby of its San Gabriel, California, headquarters
• Warren Wang, CEO of CIIX, sets goal of profitability in FY2018

ChineseInvestors.com, Inc. (OTCQB: CIIX) remains diverse, but it has realigned and set a goal of profitability in FY2018 as it increases its core investor relations revenues and offerings while reaffirming its educational services in its cryptocurrency division and its commitment to bitcoin (http://ibn.fm/TL4Cn).

CIIX revenues from investor relations grew in 1Q2018 to $258,366, up 186 percent from the $90,312 it recorded in 1Q2017. In FY2017, CIIX investor relations sales grew to $808,362, 130 percent higher than the $351,615 in FY2016 (http://ibn.fm/oNO9v). The company is expanding its program with such things as branding roadshows. It is also more selective in choosing its client companies and is entering into more cash compensation arrangements.

The company’s clients include those whose shares are traded in various public markets, including the OTCQB Venture Market, NASDAQ and NYSE. CIIX also provides consulting services, such as advertising and public relations support services, to smaller private companies considering going public.

CIIX is a diverse educational and consulting company whose audience is the global Chinese-speaking community. Its primary revenue streams include subscriptions and investor relations. Most recently, it introduced a new cryptocurrency division focused on the education of investors and potential investors regarding bitcoin. Warren Wang, CEO of CIIX, has set a goal of achieving profitability for CIIX in FY2018.

The company’s cryptocurrency division will focus on educational services for Chinese-speaking investors. Currently, that division includes a daily video from the NYSE, titled ‘Bitcoin Multimillionaire’, and CIIX has hosted a bitcoin ATM in the lobby of its San Gabriel, California, headquarters (http://ibn.fm/O9z98).

For more information, visit the company’s website at www.ChineseInvestors.com

Let us hear your thoughts: ChineseInvestors.com, Inc. Message Board

• Holds 6 U.S. patents covering biosynthesis of cannabinoids, including first U.S. issued patent to create water-soluble cannabinoids
• Aggressively seeking intellectual property patent protection in key countries worldwide
• Able to manufacture kilogram quantities of 18 naturally occurring cannabinoids through biosynthetic processes
• Canadian subsidiary holds controlled substances license from Health Canada

Teewinot Life Sciences is an international biopharmaceutical company focused on the use of synthetic biology and advanced formulation for the production and implementation of cannabinoid-based therapies. Headquartered in Tampa, Florida, Teewinot is a global leader in the formulation, manufacturing and delivery of products containing cannabinoids, cannabinoid prodrugs, and cannabinoid analogs. The company’s wholly owned subsidiaries in Ireland and Canada, along with collaborations formed with key research institutions, consumer product companies, manufacturers, and local communities, combine cutting-edge scientific research on cannabinoids with an aggressive intellectual property portfolio to create new and improved patient therapies.

Teewinot’s experienced in-house Research and Development team utilizes a powerful array of technologies for the efficient and cost-effective production of authentic cannabinoids, cannabinoid pro-drugs and cannabinoid analogs. By combining synthetic biology, biocatalysis, chemical synthesis, bioinformatics and metabolomics, authentic cannabinoids are produced that have the identical chemical structure of cannabinoids naturally produced in the cannabis plant in small quantities. Through its partnerships with leading universities and pharmaceutical companies, Teewinot is working to move the development of these proprietary compounds into clinics to provide novel patient therapies.

Full Spectrum Laboratories Ltd. and Canadian Medical Hemp Biotechnologies, Inc., Teewinot’s wholly owned subsidiaries who develop its proprietary and cost-effective methods for biosynthesis of cannabinoids, are in strict compliance with all applicable government regulations within each operating jurisdiction. Canadian Medical Hemp Biotechnologies, Inc., located near Winnipeg, Manitoba, Canada, holds a controlled substances license from Health Canada to work with cannabinoids. A recently expanded main laboratory facility houses significant research capacities in the fields of microbiology, molecular biology, chemistry, genetics and formulation technologies. A planned expansion into a second laboratory in Vancouver, British Columbia, Canada, will further enhance in-house capabilities in synthetic biology, biosynthesis, biocatalysis, microbiology and organic chemistry.

Full Spectrum Laboratories Ltd., headquartered in Dublin, Ireland, owns the corporation’s intellectual property and is engaged in licensing activities. FSL’s location within the European Union provides beneficial access to significant global markets.

Teewinot enjoys commercial first-mover advantage in the field of cannabinoid biosynthesis with patents covering biosynthetic processes and equipment for the manufacture of cannabinoids, as well as water-soluble cannabinoid formulation technology. Teewinot’s disciplined approach to research and development targets specific applications, which allows for customized product solutions and formulation challenges. Teewinot is available to assist commercial partners in the development or manufacture of new cannabinoid-based pharmaceuticals, prodrugs or analogs.

Teewinot has assembled a veteran management team with demonstrated success in leadership, growth, pharmaceutical development, marketing and aftermarket support. The organization includes a team of highly experienced scientists, business people, attorneys and other support personnel who are carefully aligning the intellectual property strategy with business goals and scientific developments. Teewinot President, Director and CEO Jeffrey M. Korentur is a co-founder of the company with more than 25 years of experience in leadership position in military and private sector roles. He is joined by Richard Peet, J.D., Ph.D., who serves as the chief intellectual property counsel; Bryan K. Brink, vice president of finance; Dr. Malcolm Kavarana, chief scientific officer and senior director intellectual property; and Eric A. Walker as chief information officer.

Teewinot’s strengths lie in its commitment to innovative research that unlocks the medicinal properties found within the cannabis plant, its disciplined approach to research and development with targeted applications, and its determination to connect and collaborate with research institutions, consumer product companies, manufacturers, local communities, and team members. Teewinot’s global technology and intellectual property represent a breakthrough in the creation and delivery of cannabinoid based medicines.

For more information, visit the company’s website at www.TLSCorp.com

Let us hear your thoughts: Teewinot Life Sciences Message Board

• Global mobile online gaming activities estimated at $48.3 billion in 2018
• Cutting edge Universal Mobile Interface ™ allows full service in any mobile device
• Competitive advantage in mobile markets driven by company’s rich history in FinTech lead transaction processing
• End-to-end FinTech solution for various vertical markets

Consorteum Holdings, Inc. (OTC: CSRH) is a software development and mobile solutions company focused on the delivery of digital offerings to mobile devices. The company provides mobile offerings, delivery of mobile content, mobile payments solutions and products through a mix of direct offerings, partnerships, license agreements and joint venture arrangements. A multi-year transition from a transaction management company focused on transaction processing solutions and products for the payment processing and financial transaction markets to multiple business verticals deepens the company’s commitment to deliver innovating solutions to end users who are using smart handset devices in radical new ways.

Consorteum Holdings, utilizing its Universal Mobile Interface™ (“UMI”) solution, offers opportunities in numerous markets with its capacity to support fully regulated, regionally compliant financial and social transactions via web and mobile. The company’s UMI technology has the capacity to provide solutions in FinTech, data analytics, secure payment processing, compliance lead transaction management and various digital social event sectors. The UMI platform allows cross operating system development to support all mobile devices while addressing the complex and highly regulated needs of the mobile FinTech industry.

Led by the development team at Consorteum’s wholly owned subsidiary 359 Mobile Inc., the Company has created an end-to-end FinTech solution utilizing the company’s UMI technology platform. Current mobile application and transaction solutions are plagued by poor experiences. Because UMI’s technology platform is designed to work across innovative payment, experience and product solutions, 359 Mobile believes there are both direct and partnership opportunities for the 359 Mobile UMI solution.

Consorteum’s primary sales and marketing strategy is focused on enabling and delivering solutions to the global mobile FinTech market with an emphasis initially on mobile gaming. The trend towards increased mobile gambling supports the need for a mobile platform such as the UMI to meet existing and new compliance regulations for the online gambling industry. The online gambling market is projected to double to nearly $1 trillion by 2021, according to a study by Juniper Research, with the majority of growth in this sector attributed to mobile devices. Consorteum’s management team believes there are fresh opportunities in this sector such as Mobile Marketing Services providing one-to-one marketing experiences for consumers; offering real-time services to Mobile Sports Book operators; and providing fixed odds betting solutions as well as social-based transactional solutions.

Consorteum’s management team includes Chairman and CEO Craig A. Fielding, a co-founder of the company with extensive experience in technology, programming and large system building; and Chief Operating Officer Patrick Shuster, who has over 25 years of business experience in sales, engineering, operations and marketing for the telecommunications industry. They are joined by John Osborne, SVP of Technology of ThreeFiftyNine Inc., an innovator in embedded systems hardware and software design; Patrick Doran, SVP of business development and marketing with over 30 years of diversified experience in major corporations as well as early stage companies; and Glenn Charlesworth, VP of Accounting, a seasoned executive with a solid track record in financial reporting, strategic planning, general management and operations, finance, start-up situations, and cash flow challenged operations.

Consorteum Holdings is committed to bridging the mobile divide by providing mobile connectivity, secure transactional processing and social connectivity solutions for both cloud and hosted based offerings in multiple business sectors.

For more information, visit the company’s website at www.Consorteum.com

Let us hear your thoughts: Consorteum Holdings, Inc. Message Board

• Biotech company focused on production of cutting-edge industrial hemp, cannabis/cannabidiol (CBD) products
• R&D efforts include nutraceuticals, pharmaceuticals, bioceuticals, phytoceuticals and cosmeceuticals catering to health, wellness and alternative medicine markets
• International provisional patent application targets CBD’s powerful medicinal benefits
• Integration of CBD molecule with generic drug molecules opens new medical frontier
• U.S. consumer market for cannabinoid-based pharmaceuticals estimated at $50 billion by 2029
• Medical diagnostic device MSN-2 slated for clinical tests to validate detection of various STDs
• Global market for diagnostic testing of STDs expected to reach $108.5 billion by 2019

Earth Science Tech, Inc. (OTC: ETST) is an innovative biotechnology company operating in the fields of hemp cannabinoid (CBD), nutraceutical, pharmaceutical and medical device research and development. Earth Science Tech offers the highest purity and quality, full-spectrum, high-grade hemp CBD (cannabidiol) oil on the market. Made using the supercritical CO2 liquid extraction process, the company’s CBD oil is 100 percent natural and organic. Earth Science Tech has partnered with the University of Central Oklahoma and DV Biologics Laboratory to conduct research and development projects that scientifically support and advance the healthcare benefits of its high-grade hemp CBD oil.

Earth Science Tech Inc. currently has three wholly owned subsidiaries focused on developing its role as a world leader in the CBD space and expanding its work in the pharmaceutical and medical device sectors. These subsidiaries include:

• Earth Science Pharma, Inc., which is committed to development of low cost, noninvasive diagnostic tools, medical devices, testing processes and vaccines for sexually transmitted infections and/or diseases. Earth Science Pharmaceutical CEO and chief science officer Michel Aubé is leading the company’s research and development efforts. The company’s first medical device, MSN-2, is a home kit designed for the detection of STIs, such as chlamydia, from a self-obtained gynecological specimen. Earth Science Pharma is working to develop and bring to market medical devices and vaccines that meet the specific needs of women.
• Cannabis Therapeutics, Inc. (“CTI”), which is poised to take a leadership role in the development of new, leading-edge, cannabinoid-based pharmaceutical and nutraceutical products. CTI is invested in research and development to explore and harness the medicinal power of cannabidiol. The company holds a provisional application patent for a CBD product that is focused on developing treatments for breast and ovarian cancers.
• KannaBidioiD (“KBD”) provides a wide variety of products geared toward the recreational space of cannabis. KBD’s unique Kanna and CBD formulation is sold and distributed in CBD-infused edibles and vapes/e-liquids products. Kanna and CBD synergistically enhance one another, providing optimal relaxation, an uplifting sensation, enhanced focus and the added benefit of assisting with nicotine reduction therapy.

Earth Science Tech celebrated a significant, developmental year during 2017 by sharing its achievements in a condensed end-of-year report. Among the report’s highlights are the implementation of a development plan for the coming three years, which includes expanding into Canada and opening new manufacturing and shipping facilities. Of particular interest is the acquisition of Canna Inno Laboratories Inc., a company headquartered in Montreal, Quebec, Canada, which gives Earth Science Tech access to Canadian government grants offered to innovators in the pharmaceutical industry. ETST has also launched development of proprietary prophylactic therapies utilizing cannabidiol (CBD) to treat various forms of breast cancer.

In October 2017, ETST announced it is cooperating with the Clinique SIDA Amité (AIDS Friendship Clinic) for a mini-clinical trial, the last trial needed before the MSN-2 device, designed for the detection of STIs, enters molecular diagnostic trials. And in November 2017, the company began pre-launch human trials on a new CBD formula to fight against the U.S. opioid epidemic. The new formula, expected to decrease cravings and the negative effects of withdrawal in addicts, is based on industrial hemp CBD mixed with a known natural ingredient proven to help increase dopamine levels. ETST’s medical devices will first be launched in Vietnam, Djibouti and Morocco while the company awaits regulatory permission to enter the North American market.

The company expects to up-list to the OTCQB in early 2018, which management believes will attract well-funded institutional investors and pave the way to becoming the next billion-dollar-in-capitalization company on the OTC markets. Other highlights include completion of the company’s Scientific Advisory Council with a team of recognized scientists, the launching of several CBD-infused edible products and entry into the medical devices market through collaborative partnerships.

Earth Science Tech has signed a collaborate agreement with Laboratories BNK Canada, a private laboratory that will conduct the clinical studies necessary for MSN-2 medical device-related services to meet regulatory requirements. ETST has confirmed the MSN-2 device’s ability to detect chlamydia, and is working to validate similar results for gonorrhea, both highly infectious diseases that often have permanent consequences for patients. ETST will also add testing for trichomoniasis and a complete body fluid panel to detect the different serotypes of the human papillomavirus (HPV) that causes cervical cancer. These additions will help the company create sales opportunities in the global market for diagnostic testing of STDs that Transparency Market Research has indicated will grow to $108 billion by 2019.

Cannabis Therapeutics is in the development stage of two cannabinoid-based pharmaceutical drugs and three cannabinoid-based nutraceutical products targeting a variety of ailments such as anxiety, depression, triple negative breast cancer, and fatty liver disease, among others. Research into the benefits of the non-psychoactive cannabinoid molecules found in the cannabis plant is supported by ETST’s International Application for Provisional Patent titled “Cannabidiol Compositions Including Mixtures and Uses Thereof,” which was filed on October 8, 2015. Cannabis Thera’s R&D efforts are concentrated on developing CBD-based drugs and nutraceutical products and in working to integrate the CBD molecule with existing generic drug molecules to create more efficient medications with fewer and less severe side effects. A report in Hemp Business Journal predicts the CBD consumer market will grow to $2.1 billion by 2020, while other industry experts expect an increase to almost $3 billion by 2021. A recent report by Statista projects the U.S. consumer market for cannabinoid-based pharmaceuticals could reach $50 billion by the year 2029.

The management team at Earth Science Tech brings decades of invaluable experience to the nutraceutical, dietary supplement field as well as the life sciences sectors. Nickolas S. Tabraue, who serves as the president, director and chief operating officer, is an industry veteran with extensive knowledge of supplements, retail management, customer service and sales expertise. He is joined by CEO and CSO Dr. Michel Aubé, a microbiologist whose scientific research in sexually transmitted infections, cancer and stem cell biology has been widely published in several prestigious medical journals. Sergio Castillo, chief marketing officer, and Gabriel Aviles, chief sales officer, bring a wealth of marketing and sales experience to Earth Science Tech, which is complemented by Issa El-Cheikh, Ph.D., and his 25 years in the international finance, accounting, planning and execution of large scale transactions in the public and private sectors.

Earth Science Tech’s products include CBD, a natural constituent of hemp oil derived from hemp stalk and seed. EST offers CBD in the form of vitamins, minerals, herbs, botanicals, personal care products, homeopathies, functional foods and other products delivered in such forms as capsules, tablets, soft gels, chewables, liquids, creams, sprays, powders and whole herbs. Earth Science products can be found at retail stores throughout the United States and are available for purchase through the internet.

For more information, visit the company’s website at www.EarthScienceTech.com